Form 4: Corvus Pharmaceuticals Executive Acquires Stock Options

Jeffrey Arcara, Chief Business Officer of Corvus Pharmaceuticals, acquired stock options for 400,000 shares of common stock on February 28, 2024.

Summary

• Jeffrey Arcara, the Chief Business Officer of Corvus Pharmaceuticals, acquired stock options on February 28, 2024.
• The options grant him the right to buy 400,000 shares of Corvus Pharmaceuticals' common stock at an exercise price of $2.30 per share.
• The options vest in equal monthly installments over three years, starting from February 2, 2024, contingent upon Arcara's continued employment with the company.
• The options expire on February 28, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The granting of stock options to a key executive like the Chief Business Officer can be seen as an incentive to align their interests with the long-term success of the company.
• The vesting schedule encourages continued service and dedication from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The size and vesting schedule of the grant are typical for executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their executives.
• The vesting schedule of 3 years is also typical, aligning with industry norms for retaining key personnel.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the Chief Business Officer to work towards increasing shareholder value.

Key Dates